Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy

Related Clinical Trial
A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) CIDP07 Rozanolixizumab Post Trial Access Program (the PTA) Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Hizentra® in Inflammatory Neuropathies – pHeNIx Study Proof-of-concept Study for BIVV020 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC) InertiaLocoGraphy as a Biomarker of Immunoglobulin Therapy Efficacy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Study Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy A Registered Cohort Study of Immune-Mediated Neuropathies Interest of Mycophenolate for CIDP Weaning Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Transcriptome Analysis of the Peripheral Blood in CIDP Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP Subcutaneous Immunoglobulin for CIDP Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy MRI in Diagnosing and Monitoring CIDP High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Panzyga in CIDP Administered at Different Infusion Rates Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Brief Title

Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy

Official Title

Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy-A Randomized, Double-Blind, Placebo Controlled Pilot Study

Brief Summary

      The purpose of the study is to examine if alpha lipoic acid is an effective treatment for
      chronic inflammatory demyelinating polyneuropathy (CIDP).
    

Detailed Description

      Chronic inflammatory demyelinating polyneuropathy (CIDP) is a progressive disease leading to
      paralysis. CIDP is an immune-mediated disorder resulting from a synergistic interaction of T
      cell-mediated and B cell-mediated immune responses directed against peripheral nerve
      antigens. These immune mediated responses in turn increase the production of reactive oxygen
      intermediate and cause oxidative damage of the peripheral nerve system. Although
      corticosteroids, plasma exchange, and intravenous immunoglobulin (IVIg) reduce impairment
      caused by CIDP at least temporarily and can be used as a first-line treatments, they are not
      ideal for long-term treatment because of serious side effects and cost. Alpha lipoic acid
      (LA) is an antioxidant that also possesses anti-immune activity. It is effective in treating
      diabetic neuropathy. It is also promising in treating patients with multiple sclerosis.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Muscle Strength

Secondary Outcome

 Hughes Functional Disability Scale

Condition

CIDP

Intervention

lipoic acid

Study Arms / Comparison Groups

 Lipoic acid
Description:  alpha lipoic acid

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

7

Start Date

February 2009

Completion Date

January 2013

Primary Completion Date

January 2013

Eligibility Criteria

        Inclusion Criteria:

          -  diagnosis of CIDP

          -  on a stable dose of immunotherapy for at least 3 months before enrolling in the study

        Exclusion Criteria:

          -  myelopathy or evidence of central demyelination

          -  persistent neurological deficits from stroke, CNS trauma, or peripheral neuropathy
             from other causes (eg, diabetes mellitus, IgM, paraproteinaemia, or uraemic, toxic, or
             familial neuropathy)

          -  evidence of systemic disease that might cause neuropathy

          -  heart diseases (congestive heart failure or arrhythmia)

          -  pulmonary conditions (asthma or CIPD)

          -  rheumatoid conditions (such as rheumatoid arthritis)

          -  renal failure
      

Gender

All

Ages

18 Years - 80 Years

Accepts Healthy Volunteers

No

Contacts

Jau-Shin Lou, MD, PhD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT00962429

Organization ID

CMT-Lou


Responsible Party

Sponsor

Study Sponsor

Oregon Health and Science University

Collaborators

 Collins Medical Trust

Study Sponsor

Jau-Shin Lou, MD, PhD, Principal Investigator, Oregon Health and Science University


Verification Date

August 2020